Affinage

MYO6

Unconventional myosin-VI · UniProt Q9UM54

Length
1294 aa
Mass
149.7 kDa
Annotated
2026-06-10
63 papers in source corpus 18 papers cited in narrative 18 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

MYO6 is an actin-based motor that drives the early steps of endocytic trafficking, moving newly uncoated vesicles from the cortical actin mesh to the early endosome (PMID:12857860, PMID:15004223). Its motor activity is required to traverse the cortical actin network: a mutant locked in tight F-actin binding immobilizes vesicles and stalls transferrin delivery, a block relieved by actin depolymerization (PMID:15004223). The catalytic core couples nucleotide hydrolysis to processive movement, and motor-domain lesions that lower actin-activated ATPase activity or disrupt inter-head gating abolish processivity and cargo transport (PMID:18833301). This motor output is tuned post-translationally: DYRK2 phosphorylation at S267 in the motor domain remodels the insert-1 network to accelerate ATPase and roughly quadruple motor speed (PMID:39112473), while USP7-mediated deubiquitination stabilizes MYO6 protein levels (PMID:40446734). MYO6 acts through a C-terminal cargo-binding tail that engages multiple adaptors to specify distinct functions (PMID:31206648); through GIPC and TOM1/TOM1L2 it positions APPL1/RAB5 signaling endosomes at the cell cortex to sustain AKT phosphorylation and RAC-dependent membrane ruffling (PMID:28591580), and proximity-labeling defines RhoGEF-containing adaptor complexes (LARG-based LIFT and DOCK7-based DISP) that link MYO6 to endosome positioning and septin cytoskeletal architecture (PMID:29467281). A planar-polarized MYO6–DOCK7–RAC1 axis restricts RAC1 activity to drive cryptic lamellipodia and collective epithelial motion (PMID:37590133). In the inner ear, MYO6 is essential for stereocilia/microvilli architecture and hair cell function, with motor- and tail-domain variants causing structural hair bundle defects and supporting pathogenicity of hearing-loss variants (PMID:18833301, PMID:37096733, PMID:32143290, PMID:35328790).

Mechanistic history

Synthesis pass · year-by-year structured walk · 9 steps
  1. 2003 High

    It was unknown which motor moved nascent endocytic vesicles after clathrin uncoating; this established MYO6 as the motor recruited immediately post-uncoating and required for vesicle delivery to the early endosome.

    Evidence Immunolocalization, pulse-chase transferrin uptake, and dominant-negative tail overexpression in epithelial cells

    PMID:12857860

    Open questions at the time
    • Did not resolve directionality or motor mechanics
    • Role of GIPC in cargo attachment inferred from co-localization, not function
  2. 2004 High

    Whether MYO6 actively transports or merely tethers vesicles was unresolved; epistasis with actin showed its motor activity is needed to move uncoated vesicles through the cortical actin mesh.

    Evidence Time-lapse imaging, dominant-negative motor mutant, and actin-depolymerization rescue of transferrin trafficking

    PMID:15004223

    Open questions at the time
    • Did not characterize ATPase kinetics underlying movement
    • Adaptor specifying this step not defined
  3. 2008 High

    The link between motor biochemistry and tissue phenotype was untested; a motor-domain mutation showed reduced ATPase and disrupted inter-head gating abolish processivity, causing both trafficking failure and inner-ear structural defects.

    Evidence ENU Tailchaser mouse, actin-activated ATPase assay, trafficking assay, and scanning EM of hair bundles

    PMID:18833301

    Open questions at the time
    • Single mutation; full structure-function map of motor domain incomplete
    • Mechanism connecting trafficking defect to stereocilia morphology not resolved
  4. 2016 Low

    Beyond bulk endocytic cargo, the breadth of MYO6-dependent trafficking was unclear; an RNAi screen and prostate cancer knockdowns placed MYO6 in nanoparticle trafficking and in AKT/ERK-linked proliferation control.

    Evidence RNAi high-content screen for nanoparticle trafficking; shRNA knockdown with cell-cycle and PathScan signaling analysis in prostate cancer cells

    PMID:27374232 PMID:27431378

    Open questions at the time
    • RNAi screen had no mechanistic follow-up for MYO6
    • No pathway rescue to confirm causality of AKT3/ERK changes
  5. 2017 High

    How MYO6 contributes to signaling beyond cargo delivery was unknown; it was shown to position APPL1/RAB5 signaling endosomes at the cortex via GIPC and TOM1/TOM1L2 to sustain AKT phosphorylation and RAC-dependent ruffling, and to be hijacked by Salmonella effectors to control phosphoinositides at invasion foci.

    Evidence siRNA knockdown with endosome positioning, phospho-AKT, PI(3)P and ruffling readouts; cell-free SopE reconstitution and phosphoinositide imaging at invasion foci

    PMID:28348208 PMID:28591580

    Open questions at the time
    • Direct mechanism coupling endosome position to AKT signaling not fully defined
    • How effectors recruit MYO6 mechanistically incomplete
  6. 2018 High

    The full adaptor interactome linking MYO6 to the cytoskeleton was undefined; proximity labeling identified two RhoGEF-containing complexes (LIFT/LARG and DISP/DOCK7) connecting MYO6 to actin-driven endosome positioning and septin architecture.

    Evidence BioID proximity-labeling proteomics with biochemical and functional validation

    PMID:29467281

    Open questions at the time
    • Stoichiometry and regulation of each complex not resolved
    • How tail switching between adaptors is controlled unclear
  7. 2023 Medium

    Whether MYO6 adaptor activity scales to multicellular behavior was untested; a planar-polarized MYO6–DOCK7–RAC1 axis was shown to spatially restrict RAC1 to drive cryptic lamellipodia and collective epithelial migration, and parallel work tied MYO6 to osteoclast podosome organization and hair-cell cuticular plate formation via GIPC3.

    Evidence siRNA knockdown with RAC1 biosensor and live imaging in epithelial monolayers; MYO6/Gipc3 KO mouse phenotyping; osteoclast KO with FAK/AKT and integrin-β3/Src readouts

    PMID:37096733 PMID:37590133 PMID:37816396

    Open questions at the time
    • Single-lab studies for each context
    • Direct biochemistry of MYO6–DOCK7 binding within the polarized axis not fully detailed
  8. 2024 High

    How motor output and protein levels are regulated, and how MYO6 is controlled transcriptionally in disease, were open; DYRK2 phosphorylation at S267 was shown to accelerate ATPase and motor speed, and AR was shown to transcriptionally induce MYO6 to drive FAK signaling in prostate cancer.

    Evidence In vitro DYRK2 phosphorylation with gliding, optical-tweezer and stopped-flow assays plus MD simulation; ChIP and FAK-Y397 functional rescue in CRPC models

    PMID:39112473 PMID:39449086

    Open questions at the time
    • Physiological contexts where S267 phosphorylation operates not mapped
    • Whether DYRK2 regulation intersects AR-driven MYO6 function unknown
  9. 2025 Medium

    New cargo-selective and stability-regulating roles emerged; MYO6 was shown to bridge GSDME-NT and AP2 for endolysosomal degradation (enhanced by spermidine binding to inhibit pyroptosis), and USP7 was shown to stabilize MYO6 via deubiquitination.

    Evidence Co-IP of MYO6–GSDME-NT–AP2 ternary complex, spermidine binding and degradation assays with tumor models; Co-IP and cellular ubiquitination assay for USP7

    PMID:40038267 PMID:40446734

    Open questions at the time
    • Single Co-IP-based studies without reciprocal structural validation
    • How spermidine reshapes cargo selectivity structurally unresolved

Open questions

Synthesis pass · forward-looking unresolved questions
  • How the C-terminal tail integrates competing adaptors to switch MYO6 between autoinhibited, dimerized, and cargo-selective states in a given cellular context remains unresolved.
  • No unified structural model of tail-mediated conformational/adaptor switching
  • Coordination between phosphoregulation, ubiquitin turnover, and adaptor binding undefined

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0003774 cytoskeletal motor activity 3 GO:0008092 cytoskeletal protein binding 3 GO:0060090 molecular adaptor activity 3 GO:0140657 ATP-dependent activity 3
Localization
GO:0005768 endosome 2 GO:0005856 cytoskeleton 2 GO:0005886 plasma membrane 2 GO:0031410 cytoplasmic vesicle 2
Pathway
R-HSA-162582 Signal Transduction 3 R-HSA-5653656 Vesicle-mediated transport 3 R-HSA-9709957 Sensory Perception 3
Partners
AP2DOCK7DYRK2GIPCGSDMERAC1TOM1USP7
Complex memberships
DISP (DOCK7-containing MYO6 complex)LIFT (LARG-containing MYO6 complex)

Evidence

Reading pass · 18 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2003 Myo6 is recruited to newly uncoated endocytic vesicles immediately after clathrin removal and is required for efficient transport of these nascent vesicles from the actin-rich cell periphery to the early endosome. Overexpression of the cargo-binding tail domain (GFP-M6tail) displaced endogenous myo6 from these vesicles and caused significant delay in transferrin uptake, with transferrin accumulating in uncoated vesicles at the cell periphery. GIPC, a putative myo6 tail binding protein, was co-present on these vesicles. Immunolocalization, pulse-chase transferrin uptake assay, GFP-tagged domain overexpression (dominant negative), subcellular fractionation Molecular biology of the cell High 12857860
2004 Myo6 motor activity is required to move uncoated endocytic vesicles through the cortical actin mesh after clathrin-mediated endocytosis. In the absence of myo6 motor activity, uncoated vesicles remain trapped in the actin mesh and undergo slow diffusion-based exit, delaying transferrin delivery to the early endosome. A myo6 mutant that binds tightly to F-actin immobilized vesicles and blocked trafficking; actin depolymerization rescued this block and specifically accelerated transferrin delivery. Time-lapse microscopy, dominant-negative myo6 motor mutant expression, actin depolymerization rescue, transferrin trafficking assay Molecular biology of the cell High 15004223
2008 A missense mutation D179Y in the motor domain of myosin VI (near the nucleotide-binding pocket, Tailchaser mouse model) decreases actin-activated ATPase rates and disrupts coordination (gating) between the two myosin VI heads in the dimer form, abolishing processive walking along or anchoring to actin filaments. This leads to failure to transport endocytic vesicles to the early endosome and structural defects (mislocalized kinocilia, branched stereocilia) in inner ear hair cells. ENU mutagenesis mouse model, actin-activated ATPase assay, GFP-myosin VI endocytic trafficking assay in epithelial cells, scanning electron microscopy of hair bundles PLoS genetics High 18833301
2017 MYO6 and its cargo adaptors GIPC and TOM1/TOM1L2 localize to APPL1- and RAB5-positive signaling endosomes at the cell cortex. Loss of MYO6 displaces these endosomes from the cortex to the perinuclear space, causes accumulation of F-actin and PI(3)P (markers of endosome maturation), and markedly reduces AKT phosphorylation and RAC-dependent membrane ruffling in response to extracellular stimuli. siRNA knockdown, immunofluorescence, phospho-AKT Western blot, membrane ruffling assay, lipid PI(3)P staining Cell reports High 28591580
2017 Salmonella effector SopE triggers MYO6 localization to bacterial invasion foci via PAK activation, and the effector SopB requires MYO6 to regulate localization of PIP3 and PI(3)P at invasion foci and Akt activation, facilitating recruitment of cytoskeletal adaptor proteins and pathogen uptake. Knockdown of MYO6 significantly reduced Salmonella invasion. Cell-free reconstitution of SopE/RhoGTPase actin polymerization at model membranes, siRNA knockdown, immunofluorescence of phosphoinositides and MYO6 at invasion foci Proceedings of the National Academy of Sciences of the United States of America High 28348208
2018 Proximity labeling proteomics (BioID) identified two distinct MYO6 adaptor complexes containing RhoGEFs: (1) the LIFT complex (LARG-Induced F-actin for Tethering), which controls endosome positioning and motility through RHO-driven actin polymerization; and (2) the DISP complex (DOCK7-Induced Septin disPlacement), a novel regulator of the septin cytoskeleton. These complexes place MYO6 at the nexus of endosome dynamics and cytoskeletal architecture. BioID proximity labeling proteomics, biochemical validation, functional analysis of endosome positioning and septin cytoskeleton EMBO reports High 29467281
2023 MYO6 forms a planar-polarized axis with DOCK7 and RAC1 in epithelial monolayers, where MYO6 recruits DOCK7 (a RAC1 GEF) to spatially restrict RAC1 activity in follower cells, promoting cryptic lamellipodia extension, tissue fluidification, and cooperative collective motion. siRNA knockdown, live imaging, RAC1 biosensor/activity assay, DOCK7 interaction studies in mammary epithelial monolayers Cell reports Medium 37590133
2024 Phosphorylation of MYO6 at serine 267 (S267) in the motor domain by the kinase DYRK2 accelerates ATPase activity, resulting in a ~4-fold increase in motor speed (actin-gliding assays), faster nucleotide-exchange kinetics (stopped-flow kinetics), and increased stiffness of the acto-MYO6 complex in the rigor state (optical tweezers), converting MYO6 into a faster and stronger motor. Molecular dynamics simulations suggest S267-phosphorylation remodels the insert-1 interaction network. In vitro phosphorylation assay with DYRK2, actin-gliding assay, single-molecule optical-tweezer mechanics, stopped-flow kinetics, molecular dynamics simulation Nature communications High 39112473
2023 GIPC3 binds directly to MYO6 in inner ear hair cells; loss of MYO6 leads to altered distribution of GIPC3. GIPC3 and MYO6 are proposed to couple to PDZ-binding motif-containing cytoskeletal and cell-junction proteins to shape the cuticular plate. Direct binding assay (GIPC3-MYO6 interaction), immunoaffinity purification from chicken inner ear, Gipc3 knockout mouse phenotyping, immunofluorescence Journal of cell science Medium 37096733
2025 MYO6 bridges the GSDME N-terminus (GSDME-NT) and the endocytic adaptor AP2, mediating endolysosomal degradation of GSDME-NT (a pyroptosis effector). The methionine-derived metabolite spermidine binds directly to MYO6 and enhances MYO6 selectivity for GSDME-NT, increasing its endolysosomal degradation and inhibiting GSDME-mediated pyroptosis. Co-immunoprecipitation (MYO6-GSDME-NT-AP2 complex), direct binding assay (spermidine-MYO6), endolysosomal degradation assay, in vivo tumor models Nature communications Medium 40038267
2025 USP7 stabilizes and upregulates MYO6 protein expression by inducing MYO6 deubiquitination. Interaction between MYO6 and USP7 was demonstrated by co-immunoprecipitation; cellular ubiquitination assays confirmed USP7-mediated removal of ubiquitin from MYO6. Co-immunoprecipitation, cellular ubiquitination assay, USP7 knockdown with MYO6 overexpression rescue Mutation research Medium 40446734
2024 Androgen receptor (AR) binds directly to the promoter region (residues −503 to −283 bp) of the MYO6 gene and promotes its transcription. MYO6 in turn activates focal adhesion kinase (FAK) phosphorylation at tyrosine-397 through integrin beta 8 (ITGB8) modulation, promoting prostate cancer progression and enzalutamide resistance. FAK inhibition by Y15 resensitized CRPC cells to enzalutamide. Chromatin immunoprecipitation (AR binding to MYO6 promoter), PathScan/Western blot (FAK-Y397 phosphorylation), MYO6 knockdown and overexpression, xenograft mouse model Cell communication and signaling : CCS Medium 39449086
2023 MYO6 is essential for osteoclast podosome organization by modulating FAK/AKT and integrin-β3/Src signaling pathways, and mediates endosome transportation by regulating Rab5 and GM130 expression. MYO6 knockout mice showed impaired NFATc1 induction and reduced osteoclast differentiation, and attenuated arthritis development in the collagen-induced arthritis model. MYO6 knockout mice, micro-CT of joint erosion, in vitro osteoclastogenesis assay, immunofluorescence for podosome formation and endosome markers (Rab5, GM130), pathway analysis (FAK/AKT, integrin-β3/Src) Biochimica et biophysica acta. Molecular basis of disease Medium 37816396
2016 MYO6 knockdown in prostate cancer cells (DU145, PC-3) suppresses cell proliferation and induces cell cycle arrest at G2/M and sub-G1 phases. PathScan array analysis demonstrated that knockdown of MYO6 downregulates phosphorylation of ERK1/2 and PRAS40, and downregulates AKT3 expression. shRNA knockdown, MTT/colony formation assay, flow cytometry cell cycle analysis, PathScan intracellular signaling array, Western blot Oncology reports Medium 27431378
2020 MYO6 variants introduced by site-directed mutagenesis into MYO6 cDNA and co-expressed with espin1 in epithelial cells produced severely shortened microvilli compared to wild-type MYO6 co-expression, which generated long microvilli. This functional assay supports the pathogenicity of hearing-loss-associated MYO6 missense variants and links MYO6 motor function to microvilli/stereocilia morphogenesis. Site-directed mutagenesis, overexpression in epithelial cells, espin1-induced microvilli formation assay, morphometric analysis Genes Medium 32143290
2022 The MYO6 p.E60Q variant reduces ATPase activity and decreases MYO6 expression at the plasma membrane in HeLa cells compared to wild-type MYO6. In zebrafish, the p.E60Q variant caused severe otic defects including altered saccule/utricle sizes and super-coiled, bent hair bundles in otic hair cells. Transient transfection of HeLa cells with MYO6WT or MYO6p.E60Q, ATPase activity assay, zebrafish morpholino knockdown-rescue model, confocal imaging of otic structures International journal of molecular sciences Medium 35328790
2019 The MYO6 C-terminal tail domain mediates cargo recognition and binding but also controls the inactive folded conformation and dimerisation of MYO6, such that adaptor binding not only triggers cargo attachment but also modulates motor activity. Multiple direct binding partners including optineurin, TAX1BP1, NDP52, Dab2, GIPC, TOM1, and LMTK2 mediate distinct functions of different MYO6 isoforms along the endocytic pathway. Review and synthesis of functional proteomics, yeast two-hybrid, affinity pulldown, biochemical assays described across multiple studies (as summarized in review) FEBS letters Low 31206648
2016 RNAi screen in HeLa cells identified myosin VI (MYO6) as required for intracellular trafficking of fluorescently-labeled polystyrene nanoparticles, placing MYO6 in the endocytic trafficking pathway for nanoparticle cargo. RNA interference high-content screening microscopy (408 genes), quantitative fluorescence microscopy Scientific reports Low 27374232

Source papers

Stage 0 corpus · 63 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2001 MYO6, the human homologue of the gene responsible for deafness in Snell's waltzer mice, is mutated in autosomal dominant nonsyndromic hearing loss. American journal of human genetics 193 11468689
2003 Myo6 facilitates the translocation of endocytic vesicles from cell peripheries. Molecular biology of the cell 158 12857860
2003 Mutations of MYO6 are associated with recessive deafness, DFNB37. American journal of human genetics 155 12687499
2017 miR-143 and miR-145 inhibit gastric cancer cell migration and metastasis by suppressing MYO6. Cell death & disease 120 29022908
2019 Circulating lncRNA UCA1 Promotes Malignancy of Colorectal Cancer via the miR-143/MYO6 Axis. Molecular therapy. Nucleic acids 100 31955010
2004 Uncoated endocytic vesicles require the unconventional myosin, Myo6, for rapid transport through actin barriers. Molecular biology of the cell 93 15004223
1997 Characterization of unconventional MYO6, the human homologue of the gene responsible for deafness in Snell's waltzer mice. Human molecular genetics 90 9259267
2008 A Myo6 mutation destroys coordination between the myosin heads, revealing new functions of myosin VI in the stereocilia of mammalian inner ear hair cells. PLoS genetics 76 18833301
2008 GOLPH2 and MYO6: putative prostate cancer markers localized to the Golgi apparatus. The Prostate 66 18543251
2021 Gene editing in a Myo6 semi-dominant mouse model rescues auditory function. Molecular therapy : the journal of the American Society of Gene Therapy 54 34174443
2017 Long non-coding RNA SOX21-AS1 sponges miR-145 to promote the tumorigenesis of colorectal cancer by targeting MYO6. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 52 29217166
2021 LncRNA UCA1 promotes development of gastric cancer via the miR-145/MYO6 axis. Cellular & molecular biology letters 46 34238213
2019 The MYO6 interactome: selective motor-cargo complexes for diverse cellular processes. FEBS letters 44 31206648
2018 The MYO6 interactome reveals adaptor complexes coordinating early endosome and cytoskeletal dynamics. EMBO reports 44 29467281
2017 MYO6 Regulates Spatial Organization of Signaling Endosomes Driving AKT Activation and Actin Dynamics. Cell reports 44 28591580
2020 HNF1A-AS1 Regulates Cell Migration, Invasion and Glycolysis via Modulating miR-124/MYO6 in Colorectal Cancer Cells. OncoTargets and therapy 42 32110048
2008 A novel nonsense mutation in MYO6 is associated with progressive nonsyndromic hearing loss in a Danish DFNA22 family. American journal of medical genetics. Part A 38 18348273
2008 A splice-site mutation and overexpression of MYO6 cause a similar phenotype in two families with autosomal dominant hearing loss. European journal of human genetics : EJHG 37 18212818
2020 Hsa_circ_0000231 knockdown inhibits the glycolysis and progression of colorectal cancer cells by regulating miR-502-5p/MYO6 axis. World journal of surgical oncology 34 32993655
2013 Progressive hereditary hearing impairment caused by a MYO6 mutation resembles presbyacusis. Hearing research 34 23340379
2003 Myo15 function is distinct from Myo6, Myo7a and pirouette genes in development of cochlear stereocilia. Human molecular genetics 30 12966030
2015 Massively parallel DNA sequencing successfully identified seven families with deafness-associated MYO6 mutations: the mutational spectrum and clinical characteristics. The Annals of otology, rhinology, and laryngology 28 25999546
2016 MYO6 knockdown inhibits the growth and induces the apoptosis of prostate cancer cells by decreasing the phosphorylation of ERK1/2 and PRAS40. Oncology reports 27 27431378
2017 MYO6 is targeted by Salmonella virulence effectors to trigger PI3-kinase signaling and pathogen invasion into host cells. Proceedings of the National Academy of Sciences of the United States of America 24 28348208
2018 MicroRNA-5195-3p plays a suppressive role in cell proliferation, migration and invasion by targeting MYO6 in human non-small cell lung cancer. Bioscience, biotechnology, and biochemistry 23 30387375
2021 LINC01224 promotes colorectal cancer progression through targeting miR-485-5p/MYO6 axis. World journal of surgical oncology 20 34535152
2016 A systematic High-Content Screening microscopy approach reveals key roles for Rab33b, OATL1 and Myo6 in nanoparticle trafficking in HeLa cells. Scientific reports 20 27374232
2021 Circ_0026416 downregulation blocks the development of colorectal cancer through depleting MYO6 expression by enriching miR-545-3p. World journal of surgical oncology 19 34645476
2019 A humanized mouse model, demonstrating progressive hearing loss caused by MYO6 p.C442Y, is inherited in a semi-dominant pattern. Hearing research 18 31103816
2020 Clinical Characteristics and In Vitro Analysis of MYO6 Variants Causing Late-Onset Progressive Hearing Loss. Genes 17 32143290
2020 CircCSNK1G1 Contributes to the Development of Colorectal Cancer by Increasing the Expression of MYO6 via Competitively Targeting miR-455-3p. Cancer management and research 17 33061642
2009 Genotype-phenotype correlation for DFNA22: characterization of non-syndromic, autosomal dominant, progressive sensorineural hearing loss due to MYO6 mutations. Audiology & neuro-otology 16 19893302
2022 Circ_0011385 knockdown inhibits cell proliferation, migration and invasion, whereas promotes cell apoptosis by regulating miR-330-3p/MYO6 axis in colorectal cancer. Biomedical journal 15 35091088
2013 A novel MYO6 splice site mutation causes autosomal dominant sensorineural hearing loss type DFNA22 with a favourable outcome after cochlear implantation. Audiology & neuro-otology 13 23635807
2008 Upregulation of Myo6 expression after traumatic stress in mouse hippocampus. Neuroscience letters 13 18261850
2016 A Novel ENU-Induced Mutation in Myo6 Causes Vestibular Dysfunction and Deafness. PloS one 12 27171474
2017 Exome Sequencing Identifies a Novel Nonsense Mutation of MYO6 as the Cause of Deafness in a Brazilian Family. Annals of human genetics 11 29044474
2017 Next-generation sequencing identifies three novel missense variants in ILDR1 and MYO6 genes in an Iranian family with hearing loss with review of the literature. International journal of pediatric otorhinolaryngology 11 29224747
2014 Exome sequencing identifies a novel frameshift mutation of MYO6 as the cause of autosomal dominant nonsyndromic hearing loss in a Chinese family. Annals of human genetics 11 25227905
2013 Adaptive evolution of the myo6 gene in old world fruit bats (family: pteropodidae). PloS one 10 23620821
2024 The Suppression of the Epithelial to Mesenchymal Transition in Prostate Cancer through the Targeting of MYO6 Using MiR-145-5p. International journal of molecular sciences 9 38673886
2023 GIPC3 couples to MYO6 and PDZ domain proteins, and shapes the hair cell apical region. Journal of cell science 9 37096733
2018 A clinical guidance to DFNA22 drawn from a Korean cohort study with an autosomal dominant deaf population: A retrospective cohort study. The journal of gene medicine 9 29607572
2018 Identification of a novel MYO6 mutation associated with autosomal dominant non-syndromic hearing loss in a Chinese family by whole-exome sequencing. Genes & genetic systems 9 30175721
2023 Associations of MYPN, TTN, SCN5A, MYO6 and ELN Mutations With Arrhythmias and Subsequent Sudden Cardiac Death: A Case Report of an Ecuadorian Individual. Cardiology research 8 37936622
2023 A planar polarized MYO6-DOCK7-RAC1 axis promotes tissue fluidification in mammary epithelia. Cell reports 7 37590133
2018 Targeted Mutation Analysis of the SLC26A4, MYO6, PJVK and CDH23 Genes in Iranian Patients with AR Nonsyndromic Hearing Loss. Fetal and pediatric pathology 7 30582396
2024 Circ_0000395 promotes cell growth, metastasis and oxaliplatin resistance by regulating miR-153-5p/MYO6 in colorectal cancer. Pathology, research and practice 6 39038387
2024 MYO6 contributes to tumor progression and enzalutamide resistance in castration-resistant prostate cancer by activating the focal adhesion signaling pathway. Cell communication and signaling : CCS 6 39449086
2023 Myo6 mediates osteoclast function and is essential for joint damage in collagen-induced arthritis. Biochimica et biophysica acta. Molecular basis of disease 6 37816396
2025 Methionine metabolite spermidine inhibits tumor pyroptosis by enhancing MYO6-mediated endocytosis. Nature communications 5 40038267
2024 Motor domain phosphorylation increases nucleotide exchange and turns MYO6 into a faster and stronger motor. Nature communications 5 39112473
2022 Functional Characterization of the MYO6 Variant p.E60Q in Non-Syndromic Hearing Loss Patients. International journal of molecular sciences 4 35328790
2021 High Prevalence of MYO6 Variants in an Austrian Patient Cohort With Autosomal Dominant Hereditary Hearing Loss. Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology 4 33710140
2020 Approaches to Identify and Characterise MYO6-Cargo Interactions. Advances in experimental medicine and biology 3 32451866
2025 USP7 accelerates colorectal cancer progression by up-regulating MYO6 through deubiquitination. Mutation research 1 40446734
2024 Novel cis compound heterozygous variants in MYO6 causes early onset of non-syndromic hearing loss in a Chinese family. Frontiers in genetics 1 38274113
2024 Targeted Next-Generation Sequencing Analysis Reveals a Novel Genetic Variant in MYO6 Gene in an Indian Family with Postlingual Nonsyndromic Hearing Loss. Genetic testing and molecular biomarkers 1 39019031
2026 A novel MYO6 variant identified in a Chinese family with autosomal dominant non-syndromic hearing loss. BMC medical genomics 0 41923037
2026 MYO6 and Heart: A Novel Variant in a Deaf Infant With Supraventricular Tachycardia. Molecular genetics & genomic medicine 0 42252530
2024 In silico and in vivo analyses of a novel variant in MYO6 identified in a family with postlingual non-syndromic hearing loss from Argentina. NAR genomics and bioinformatics 0 39664812
2023 A planar-polarized MYO6-DOCK7-RAC1 axis promotes tissue fluidification in mammary epithelia. bioRxiv : the preprint server for biology 0 36747801
2023 GIPC3 couples to MYO6 and PDZ domain proteins and shapes the hair cell apical region. bioRxiv : the preprint server for biology 0 36909580

Missed literature

Know a paper Affinage missed for MYO6? Flag it for the maintainers and the community.

No submissions yet.